Does PRALSETINIB Cause Malignant neoplasm progression? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Malignant neoplasm progression have been filed in association with PRALSETINIB (Gavreto). This represents 1.0% of all adverse event reports for PRALSETINIB.
14
Reports of Malignant neoplasm progression with PRALSETINIB
1.0%
of all PRALSETINIB reports
3
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From PRALSETINIB?
Of the 14 reports, 3 (21.4%) resulted in death, 3 (21.4%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PRALSETINIB. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does PRALSETINIB Cause?
Death (126)
Fatigue (104)
Asthenia (96)
Off label use (92)
Hypertension (89)
Disease progression (85)
Anaemia (80)
Diarrhoea (79)
Pyrexia (75)
White blood cell count decreased (74)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which PRALSETINIB Alternatives Have Lower Malignant neoplasm progression Risk?
PRALSETINIB vs PRAMIPEXOLE
PRALSETINIB vs PRAMIPEXOLE\PRAMIPEXOLE
PRALSETINIB vs PRAMLINTIDE
PRALSETINIB vs PRASTERONE
PRALSETINIB vs PRASUGREL